(Enriocrinology 137: 1349-1357, 1996) P TH-RELATED I'ROTEIN (PTHrP), through its actions on bone to increase bone resorption and on kidney to restrict calcium excretion, is the tumor product responsible for the syndrome of humoral hypercalcemia of malignancy (1, 2). The amino-terminal region of PTHrP is similar to that of PTH, with 8 of the first 13 amino acids common to the 2 proteins (3). This limited homology is sufficient for the 2 molecules to bind to a common PTH/PTHrP receptor (4), which mediates the PTH-like actions of I'THrP. A second and related receptor, PTH2R, has recently been identified that recognizes PTH but not PTHrP (5). In addition to being a product of tumors, PTHrP is present in a variety of normal tissues, including skin, placenta, lactating mammary tissue, and brain (6-9), where it has other, non-PTH-like, actions. These actions include a role in placental calcium transport, mediated by a portion of the molecule between residues 35-84 (7), and inhibition of osteoclastic bone resorption in z~it~~, mediated by amino acids 107-111 of the PTHrP molecule (10). PTHrI' has also been implicated in cell growth and/or differentiation (11, 12 1. Diagrammatic representation of the genomic organization and alternative splicing of the PTHrP gene. The coding regions and the untranslated sequences are indicated by the closed and open boxes, respectively. Indicated above the mop are the three promoters, Pl, P2, and P3, of which Pl and P3 are TATA promoters (5' to exons I and IV, respectively) and P2 is a GC-rich promoter (5' to exon III). Known splicing events are also indicated. The arrows below the mop indicate the 5' to 3' orientation and the locations of the primers used for PCR analysis ofPTHrP transcripts shown in Figs. 2, 4, 5, 6, and 7 No PCR products were detected in these reactions. The PCR conditions were stringent, in that no nonspecific products were detected; only PTHrP-or GAPDHspecific products were detected, and these were confirmed by Southern blot detection using a "P-labeled internal oligonucleotide probe, as previously described (26, 28 
Results
A range of human cell lines, including those of squamous origin (BEN and COLO 16), breast (MCF7, MDA-MB-231, and T-47D), kidney (HEK293), osteogenic sarcoma (Saos-2), and normal skin (HaCaT), were examined by RT-PCR for PTHrP mRNA expression. RNA was extracted from the cell lines and reverse transcribed, and the cDNA was subjected to 40 cycles of PCR with the PTHrP exon-specific primers (Fig. 1) ; 40 PCR cycles were undertaken to ensure detection of all transcripts. PCR products were resolved on a 2.0% (wt/vol) agarose gel, transferred to nylon, and verified by hybridization with a 32P-labeled internal oligonucleotide, obrf 15.8; this method of verification of PCR products was used in all subsequent PCR analyses. PCR with primers obrf 15.84 and obrf 15.89 directed to the common exons (V and VI, respectively) demonstrated that each of the cell lines produced PTHrP mRNA (Fig. 2) . To investigate promoter usage, amplifications were carried out using oligonucleotides to each of the alternative 5'-exons adjacent to the promoters Pl (exon I; obrf 15.931, P2 (exon III; obrf 15.95), and I'3 (exon IV; obrf 15.83; Fig. 1 ). As exon III is common to both I'1 and P2 transcripts ( the use of an oligonucleotide (obrf 15.95) synthesized to the most 5'-region of P2 transcripts that initiate 11 nucleotides 5' to the splice acceptor site of exon III used by Pl-initiated transcripts (20). To determine the 3' splicing outcomes, antisense oligonucleotide primers to each of the 3' ultimate exons (VII, obrf 15.90; VIII, obrf 15.91; IX, obrf 15.92) were used. Combining the promoter-specific 5'-primers and the 3'-primers to the alternative 3'-exons permits the identification of each of the alternative PTHrP mRNA species. The BEN, COLO 16, and HaCaT cells used each of the three PTHrP promoters (Pl, P2, and P3); each of the three alternative 3' exons (VII, VIII, and IX) and each of the 3' alternative exons could be incorporated into transcripts specified by each of the three promoters (Fig. 2) . In contrast, two of the breast cell lines (MCF7 and MDA-MB-2311 and the osteogenic sarcoma cell line (Saos-2), although using each of the three promoters and each of the 3'-exons, differed in their splicing patterns. In these cell lines, I'1 transcripts contained exon IX exclusively as the 3'-exon, whereas P2 and P3 transcripts contained exon VII, VIII, or IX (Fig. 2) . The other breast cancer line (T-47D) did not use the Pl promoter, P3 transcripts did not contain exon IX, and I'2 transcripts contained exon VII, VIII, or IX as the 3'-exon. The HER293 cells did not produce Pl transcripts, I'2 transcripts containing exon VII, or P3 transcripts containing exon VIII. As a positive control for RNA purity and RT activity, reverse transcribed RNA from each cell line was amplified with primers to the housekeeping gene GAPDH, and GAPDH-specific products were verified by hybridization with GAPDH-1 (Fig. 2) ; for GAPDH, saturation of PCR conditions is achieved by 30 cycles of amplification (28). Thus, these cell lines clearly differed in the particular PTHrP mRNA species produced.
To determine whether agents that regulate PTHrP production could preferentially act through one promoter sequence or alter 3' alternative splicing, we investigated the effects of cycloheximide, dexamethasone, EGF, and TGFP on PTHrP promoter usage and mRNA splicing patterns in the BEN, COLO 16, and HaCaT cell lines, because these cell lines use all splicing pathways. The effects of these agents on total PTHrP mRNA levels in COLO 16 cells was demonstrated by Northern blot analysis with a cDNA probe to exon VI of the P7'HrP gene (Fig. 31 , which is present in all PTHrP mRNA species (Fig. 1) . Multiple hybridizing mRNA species were detected, reflecting PTHrP alternative splicing. The PTHrP signal was quantitated and normalized by reference to the GAPDH signal. Cycloheximide, EGF, and TGFP treatment increased PTHrP mRNA levels (290%, 360%, and 330%, respectively), and dexamethasone decreased PTHrP expression (44% of normal) in COLO 16 cells. The regulation of PTHrP mRNA by these agents is in agreement with previous findings in this and other cell lines, except that cycloheximide does not increase mRNA expression in all cell lines (21, 22, 26, 27, 41) .
To investigate the effects of these agents on PTHrP mRNA splicing patterns, the highly sensitive RT-PCR technique was employed, using the primers indicated in Fig. 1 . RT-PCR may be used to compare the relative amounts of a particular target sequence in different samples (e.g. control and treated) provided that the number of PCR cycles performed is within the exponential phase of the reaction, i.e. where there is a log The filter was hybridized with a 32P-labeled cDNA probe to PTHrP exon VI, after which the specific hybridization was removed, and the filter was rehybridized with a 32P-labeled GAPDH cDNA probe. The positions of the 18s and 28s ribosomal RNA bands are indicated. The intensity of the signal was quantitated by PhosphorImager analysis and normalized by reference to the GAPDH signal.
linear relationship between the number of PCR cycles and the yield of PCR products. Included for RT-PCR analysis was a reaction in which GAPDH mRNA could be amplified. This served two purposes: 1) as a positive control for the RT reaction, and 2) to act as a normalizing control for treated samples. As the control sequence is not used to define absolute levels of mRNA, differences in primer efficiencies between the control and test primers are not important as long as each is carried out at the optimal cycle number for that primer pair. To determine the optimal number of PCR cycles for each PTHrP primer pair, 0.2 /.~g RT RNA from unstimulated COLO 16 cells was subjected to PCR over a range of cycle numbers. Five microliters of the 20-~1 reaction mixture were electrophoresed through a 2% (wt/vol) agarose gel, transferred to a nylon filter, and hybridized with 32P-labeled obrf 15.8. The intensities of the hybridizing signals were quantitated by PhosphorImager analysis and plotted against cycle number, and the optimal number of cycles for each primer set was determined (see Materials and Methods). The difference in cycle number for the amplification of cDNA for PTHrP and GAPDH probably reflects the difference in the abundance of the two transcripts, with GAPDH being the more abundant and, therefore, achieving greater amplification over fewer cycles. The relative binding and amplification efficiencies of the different oligonucleotide primer pairs will also influence the optimal cycle number. Firstly, to determine whether the yield of RT-PCR products from treated cells reflected the regulation of PTHrP mRNA as determined by Northern analysis, the regulation of the product resulting from RT-PCR with primers to exons V and VI was addressed (Fig. 4A) , which reflects all PTHrP mRNA species, as these exons are present in all PTHrP tran- Amplification and detection of a specific 414-bp GAPDH mBNA PCR product was included in each experiment, and products were confirmed with 32P-labeled GAPDH-1.
scripts. PCR was carried out with the exon V and VI primers (obrf 15.84 and obrf 15.89) on reverse transcribed RNA from unstimulated and treated COLO 16 cells. The intensities of the hybridizing signals of the PTHrP PCR products were quantitated using a PhosphorImager and normalized against the GAPDH signal obtained after PCR with the GAPDH primers, GAPDH-3 and GAPDH-4. The PCR product yield correlated with the Northern blot analysis data, where cycloheximide, EGF, and TGF/3 increased, and dexamethasone decreased PTHrP mRNA steady state levels. The effects of the treatments on PTHrP PCR product yield were determined as a percentage of the control yield, as shown in Table  1 , and correlated with the magnitude of response seen on Northern blot analysis. This indicated that the RT-PCR method was appropriate for studying the regulation of splicing and exon usage of PTHrP mRNA in response to modulating agents.
As alternative 3' splicing of PTHrP transcripts results in the production of different isoforms of PTHrP, the 3' splicing events were examined by RT-PCR using a sense strandspecific oligonucleotide to the common exon V (obrf 15.84) and antisense strand-specific oligonucleotides to the alternative 3'-exons, exons VII (obrf 15.90), VIII (obrf 15.91), and IX (obrf 15.92; Fig. 4B ). In unstimulated COLO 16 cells, each of the three 3'-exons was present in mRNA transcripts, as observed in Fig. 2, indicating RNA from unstimulated and treated COLO 16 cells was reverse transcribed and subjected to PCR using the primers indicated in Fig.  1 and GAPDH-specific primers. PCR products were resolved on a 2% (wtkol) agarose gel and confirmed by Southern blot analysis with either a 32P-labeled PTHrP exon VI-specific oligonucleotide, obrf15.8, or a 32P-labeled GAPDH-specific oligonucleotide, GAPDH-1. The intensities of the hybridizing signals of the PTHrP PCR products were quantitated by PhosphorImager analysis and normalized against the appropriate GAPDH signal. The values obtained for treated cells are expressed as a percentage of the control signal. Results are the mean 2 SEM Of fOUr or five experiments. mide, EGF, and TGFP treatment of COLO 16 cells increased the levels of exon VII-, VIII-, and IX-containing transcripts. However, there appeared to be a more marked increase in exon VII-and VIII-containing transcripts (-300-400% of control levels; Table 1 ) than in exon IX-containing transcripts ( Fig. 4B and Table 1 ; -200% of control levels) in response to these treatments. Dexamethasone decreased the levels of exon VII-, VIII-, and IX-containing transcripts to approximately 40% of control levels ( Fig. 4B and Table 1 ).
To investigate promoter usage, amplifications were carried out with oligonucleotide primers to each of the alternative 5'-exons adjacent to the promoters Pl (exon I), I?2 (exon III), and P3 (exon IV) and the common exon VI (Fig. 1) . Amplification using oligonucleotides priming in exons I and VI to detect Pl-initiated transcripts resulted in three products of 739,646, and 406 bp, respectively ( Fig. 5A ; also visible in Fig. 2) . The major product of 739 bp was consistent with splicing of exons I, II, III, V, and VI, and this fragment indeed hybridized with oligonucleotides specific to each of these exons. The 646-bp product was predicted to result from splicing of exons I, III, V, and VI (i.e. excluding exon II), and this product hybridized with oligonucleotide probes to exons I, III, V, and VI, but not with an oligonucleotide specific for exon II (Fig. 5A) . The minor product of 406 bp was predicted to result from splicing of exons I, V, and VI, excluding exons II and III. In agreement, this product hybridized with oligonucleotides specific to exons I, V, and VI and to oligonucleotide obrf 15.101 complementary to the sequence of the splice donor/acceptor junction of exons I and V (Fig. 5A ). Although this is the first report of splicing of exon I to exon V for the human gene, this splicing pattern has also been probes results from the different lengths of the oligonucleotides, their different hybridization efficiencies, and the exposure times of the autoradiographs. B, 5' alternative splicing detected by amplification using oligonucleotides specific for promoter 1 (Pl; i.e. exon I sense strandspecific oligonucleotidel, promoter 2 (P2; the P2-specific oligonucleotide obrf 15.95, synthesized to the most 5'-region of promoter 2 transcripts that initiate 11 nucleotides 5' to the exon III splice acceptor site used by promoter l-initiated transcripts) (20) and promoter 3 (P3; i.e. exon IV sense strand-specific oligonucleotide). The PCR products were confirmed by hybridization with 32P-labeled obrf 15.8. Amplification and detection of a specific 414-bp GAPDH mRNA PCR product were included in each experiment, and products were confirmed with 32P-labeled GAPDH-1. observed for canine PTHrP (40). Thus, three potential 5' alternative splicing patterns may occur in Pl-initiated transcripts, with the majority of Pl-initiated transcripts including exon II.
RT-PCR analysis demonstrated that each of the three promoter regions of the PTHrP gene was used in unstimulated COLO 16 cells (Figs. 2 and 5B) . Cycloheximide, EGF, and TGFP, each of which up-regulated PTHrP mRNA levels, increased the levels of product from each promoter, but had a consistently greater effect on Pl-and P2-initiated transcripts than on P3-initiated transcripts (Fig. 5B and Table 1) . Dexamethasone, which down-regulated PTHrP expression, decreased the level of product from each of the three promoters (24) (Fig. 5B and Table 1 ).
To determine whether promoter usage may influence 3' splicing events, PCR amplifications were carried out be- Fig. 3 , and the primer combinations are described in Fig. 1 . PCR products were confirmed by hybridization with 32P-labeled obrf15.8. A, Pl-initiated transcripts to alternative 3'-exons VII, VIII, and IX. B, Pa-initiated transcripts to alternative 3' exons VII, VIII, and IX. C, P3-initiated transcripts to alternative 3' exons VII, VIII, and IX. Amplification and detection of a specific 414-bp GAPDH mRNA PCR product is shown below.
tween the Pl-, P2-, and P3-specific 5'-oligonucleotides and oligonucleotides for each of the alternative 3'-exons (Fig. 6) . It was found that transcripts resulting from each of the promoters were capable of including each of the three 3' alternative exons and that each of the transcript combinations was regulated by these agents (Table 1) . However, Pl-and P2-initiated transcripts with exons VII or VIII as the 3'-preferred alternative exon were predominantly regulated, as evidenced by the cycloheximide, EGF, and TGFP treatments (Fig. 6, A and B, and Table 1 ). The treatments did not regulate P3-initiated transcripts to the same extent ( Fig. 6C and Table  l) , which is consistent with the smaller effect of these agents on P3-initiated transcripts observed in Fig. 5B ( Table 1) . The enhancement of exon VII-and exon VIII-containing PTHrP transcripts by cycloheximide, EGF, or TGFP may result from increased processivity of these splicing pathways over that used for exon IX or preferential stabilization of transcripts containing these exons. Indeed, we previously reported that both EGF and TGFP enhance the stability of PTHrP ml2NA (22, RT-PCR was performed with primer pairs to the exons indicated at the left using the optimal number of PCR cycles for semiquantitative analysis. PCR products were confirmed by hybridization with 32P-labeled obrf 15.8 or GAPDH-1. Cells were treated with 0.8 FM actinomycin D for the times indicated, and EGF-treated HaCaT cells were exposed to EGF (5 nM) for 2 h before actinomycin D treatment.
PTHrP mRNA, assessed by RT-PCR with primers amplifying the common exons V and VI, was relatively short (-90 min; Fig. 7) . In contrast, when the HaCaT cells had been exposed to EGF for 2 h before the addition of actinomycin D, the half-life of PTHrP mRNA was increased to greater than 10 h (Fig. 7) ; this is in agreement with previous findings (41). To determine whether EGF treatment resulted in a stabilization of all PTHrP transcripts or had differential effects on the alternative PTHrP transcripts, the half-lives of PTHrP transcripts containing the alternative 3'-exons were determined. In unstimulated cells, transcripts containing exon VII or IX were found to be unstable; each had a half-life of approximately 90 min, whereas exon VIII-containing transcripts were stable, possessing a half-life of more than 10 h. In EGF-treated cells, the half-lives of exon VII-and IX-containing transcripts increased from 1.5 to more than 10 and 4.5 h, respectively, and no alteration in the half-life of exon VIIIcontaining transcripts was detected. This indicates that EGF preferentially stabilizes exon VII-and IX-containing transcripts. Furthermore, as the half-life of PTHrP transcripts is only 90 min in unstimulated cells, this suggests that exon VIIand IX-containing transcripts predominate relative to transcripts containing exon VIII, which have a half-life of more than 10 h.
Discussion
The PTHrP gene is under the control of multiple promoters and is subject to alternative splicing at both the 5'-and 3'-ends of the primary mRNA transcripts, with the 3' alternative splicing predicting three PTHrP isoforms (3, 13, (15) (16) (17) (18) (19) (20) 42) . It was, therefore, of interest to study the promoter usage and alternative splicing of this gene and determine whether the 5' and 3' splicing events are linked or independent.
Analysis of a variety of cell lines revealed that each cell line produced PTHrP transcripts containing each of the three 3' alternative exons. Thus, each cell line was potentially capable of producing each of the three isoforms of PTHrP of 139,141, and 173 amino acids. The physiological significance of these three isoforms remains to be elucidated.
As there is no interspecies sequence homology beyond amino acid 111 (1,2), it seems unlikely that these sequences mediate important biological actions. Their significance may potentially be in their properties as substrates for posttranslational processing and thereby dictate the fragments generated.
The predominant PTHrP species secreted by the BEN, COLO 16, and HaCaT cell lines approximates PTHrP-(l-108) (1, 2), which may be generated from one, two, or all three PTHrP isoforms.
Differences were noted in the promoter usage among the cell lines examined. For instance, P2 and I'3 were used by all cell lines, whereas HER293 and T-47D cells did not use Pl. Similarly, other groups noted differences in promoter usage in cell lines (42,43); however, they did not examine P2 promoter usage. Interestingly, we have shown for the first time that 3' splice site selection can be promoter specific, as exemplified by the MCF-7, MDA-MB-231, and Saos-2 cell lines, in which Pl transcripts contained only exon IX as the 3'-exon. Furthermore, in the HER293 and T-47D cell lines, the I'3 promoter did not generate transcripts containing each of the alternative 3'-exons. This alternative splicing could allow for a more subtle regulation of PTHrP isoform production. A number of agents have been described that regulate PTHrP production and mRNA levels; however, their ability to modify the relative amounts of the different PTHrP mRNA species, for example, altering the 3' splicing patterns to preferentially produce one PTHrP protein form, has not been examined. We used a combination of Northern blotting and RT-PCR techniques to address this question. Northern analysis was of limited value in studying promoter usage; whereas the detection of exons I and IV indicates the use of Pl and P3, respectively, the detection of exon III by Northern analysis is ambiguous, because exon III is a component of both Pl-and P2-initiated transcripts.
RT-PCR, however, enabled unequivocal identification of P2-initiated transcripts by taking advantage of the fact that P2 transcripts initiate 11 nucleotides 5' to the splice acceptor site of exon III; the promoter 2-specific primer was designed for this region. The RT-PCR approach also proved to be manyfold more sensitive than Northern blot analysis and allowed a uniquely detailed study of regulation of PTHrP. As PTHrP is commonly produced by squamous cell cancers as well as normal keratinocytes, we chose to study PTHrP alternative splicing in two squamous cancer cell lines, one derived from skin (COLO 16) and the other from lung (BEN), and in an immortalized keratinocyte cell line (HaCaT). These cells have previously been shown to express PTHrP mRNA and secrete PTHrP, as determined by RIA and Western blotting (16, 22, 26, 30, 41 Endo . 1996 Vol 137 . No 4 and that transcripts containing the latter exons are stabilized by EGF. Thus, EGF and TGFP appear to act via sequences in the 3'untranslated region of exons VII and IX to stabilize transcripts containing these exons. The existence of multiple copies of the AUUUA instability motif (2, 18, 19) in the 3'-untranslated region of each of the alternative 3'-exons indicates that control of mRNA stability could be important in the regulation of PTHrP expression. Importantly, exon IX contains the elemental nonamer instability motif UUAUUUAUU (45), and PTHrP transcripts containing this exon have a short mRNA half-life. Alternatively, EGF and TGFP may increase the level of Pl and P2 transcripts containing exon VII or VIII by promoting splicing of Pl and P2 transcripts to exon VII or VIII over that to exon IX. Exon IX-containing transcripts also appear to be stabilized by EGF treatment, however not to the same extent as exon VII-containing transcripts, perhaps accounting for the preferential increase in transcripts containing exon VII. The marked increase in exon VIII-containing transcripts may arise from increased splicing to exon VIII (over exon IX) and/or from the increase in such a stable transcript as that specified by exon VIII. TGFP has been shown to preferentially increase the amount of fibronectin mRNA species containing the alternatively spliced exon ED-B over those lacking this exon (46). However, the most plausible explanation is that both transcriptional and posttranscriptional mechanisms operate, with EGF and TGFP increasing PTHrP expression by increasing transcription from promoters 1 and 2 and preferentially stabilizing exon VII-containing transcripts. Thus, it should be noted, as borne out by these results, that differential promoter activity may only be assessed by this technique if the modulating agent does not regulate mRNA stability.
RT-PCR has been used in limited studies of alternative splicing and regulation of gene expression in other genes (47, 48) ; the PTHrP gene, by virtue of its three promoters and 5' and 3' alternative splicing, is a candidate gene for the demonstration of alternative splicing and promoter regulation by this technique. The technique proved to be extremely valuable in studying PTHrP alternative splicing and, in particular, examining the composition of PTHrP mRNA species with respect to their 5'-and 3'-exons. In addition, this technique proved to be more informative and less timeconsuming than Northern blotting and can be readily applied to study the expression and regulation of any gene by using a normalizing mRNA species such as we have employed.
These data indicate that regulators of PTHrP transcription also alter the mRNA splicing patterns. EGF and TGFP not only increased the expression of PTHrP, but modified the relative amounts of the different mRNA species, preferentially increasing the abundance of exon VII-and exon VIIIcontaining PTHrP transcripts. This modulation of the splicing patterns may result from a requirement for a heightened expression of the 139-or the 173-amino acid isoform or to increase the abundance of stable mRNA species, thus further increasing PTHrP expression. This may be of relevance with regard to the tissue-specific autocrine/paracrine roles of PTHrP.
